Tata Chemicals Ltd
TATACHEMTata Chemicals Ltd's price has outrun its earnings. −29.6% in a year against EPS −907.0% — the market is paying now for delivery later.
The sharpest disagreement: the price moved −29.6% in a year while annual EPS moved −907.0% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is in a downtrend (39 weeks in) while the P/E sits at the 91st percentile of its own 10-year range. Underneath, the last four quarters read deteriorating — profit −81.0% year on year, and 238% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Tata Chemicals Ltd trades at ₹674, in a downtrend and 39 weeks into that stage. That is −10.9% against its own 200-day average. It sits at 18% of a 52-week range of ₹605 to ₹994. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (7 weeks and counting).
Today the stock is in a downtrend — week 39 of stage 4, confirmed. At ₹674 it trades −10.9% versus its 200-day average and sits at 18% of its 52-week range (₹605–₹994).
Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +314% while the NIFTY 500 moved +264% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (7 weeks and counting; last ahead the week of 2026-06-24) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Tata Chemicals Ltd trades at 64.4× P/E, at the pricey end of its own range (91st percentile). Its long-run median P/E is 11.8×, measured across 10.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 64.4× is at the pricey end of its own range (91st percentile), against a long-run median of 11.8× measured over 10.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved −907.0% against a −29.6% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 5y, of the −2.5%/yr price move, ~+2.9%/yr came from earnings growth and ~−5.4 pp from the multiple (compressing); over 10y, of the +12.3%/yr price move, ~−13.0%/yr came from earnings growth and ~+25.3 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Turning around Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Tata Chemicals Ltd reads as turning around on its fundamental arc. Turning around — profit growth swung from −513.7% at the trough to −484.2% off a 1-quarter-old trough, ROCE holding at 3.1%. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: growth inflections are where re-ratings start — the curves say a turn is forming, so the question becomes whether the next quarters confirm it.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | −2.0% | −4.6% | +7.4% | −0.2% |
| Share price | −29.6% | −13.8% | −2.5% | +12.3% |
4-Factor Sector Score
27.5/100 — rank 7 of 7 in Chemicals - Inorganic - Caustic Soda/Soda Ash · 80% evidence confidence
Tata Chemicals Ltd scores 27.5 out of 100 against the 7 companies it is compared with in Chemicals - Inorganic - Caustic Soda/Soda Ash, ranking 7. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 8.1 + 6.6 + 10 + 2.8 = 27.5. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Tata Chemicals Ltd reported ₹4,255 Cr of revenue in the Jun 26 quarter, +14.4% year on year. Over 10 years it has compounded at −0.2% a year. The last full year, FY26, came in at ₹14,584 Cr. The last four reported quarters add to ₹15,120 Cr.
FY26 revenue came in at ₹14,584 Cr (−2.0% on the year), capping 10 years at −0.2% compound. The latest quarter (Jun 26) printed ₹4,255 Cr, +14.4% year on year.
Pace check: the last four quarters averaged +2.0% growth against the decade's −0.2% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +2.0% over the last 4 quarters against +0.4%/yr over the last 8 — stabilising.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Tata Chemicals Ltd's operating margin is 13.0% in the Jun 26 quarter, −4.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 4.0% to 33.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 13.0%, −4.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 4.0%–33.0%.
🚨 Why the margin moved: operating margin went −4.8 pp year on year while gross margin went −0.9 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Tata Chemicals Ltd earned ₹60.0 Cr of net profit in the Jun 26 quarter, −81.0% year on year. The full FY26 year was a loss of ₹1,715 Cr. That is 1.4% of the quarter's revenue. The same quarter a year earlier earned ₹316 Cr. 5 of the last 12 reported quarters were loss-making.
Jun 26 profit was ₹60.0 Cr, −81.0% year on year. On the full year, FY26 printed ₹−1,715 Cr (−543.2%).
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 238% of Tata Chemicals Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹1,269 Cr of operating cash against ₹−1,715 Cr of profit. After ₹1,328 Cr of capital spending, ₹−59.0 Cr was left as free cash.
FY26: operating cash of ₹1,269 Cr against reported profit of ₹−1,715 Cr, leaving free cash of ₹−59.0 Cr after ₹1,328 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 238% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 238%: the cash cycle stretched 62 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: the bigger cash user is investment — capital spending ran 1.6× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Tata Chemicals Ltd's cash conversion cycle runs 113 days in FY26, up from 51 days in FY21. Capital spending ran ₹5,442 Cr over the last 3 years. At FY26 sales of ₹14,584 Cr each day of that cycle holds about ₹40.0 Cr, so roughly ₹4,515 Cr sits inside the business at any moment.
FY26: debtors at 52 days, inventory at 353 days — roughly 11.6 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 113 days, looser than FY21's 51.
The full loop: cash goes out to suppliers and production on day 0; stock waits 353 days to sell; customers pay about 52 days after that; and suppliers themselves are paid at 293 days — netting out to the 113-day cycle.
In money terms: at FY26 sales of ₹14,584 Cr, each day of the cycle holds about ₹40.0 Cr — so the 113-day loop keeps roughly ₹4,515 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹5,442 Cr over the last 3 fiscal years against ₹3,304 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹1,038 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Tata Chemicals Ltd earns a ROCE of 3% in FY26. That is up from a trough of 3% in FY14. Return on invested capital clears the cost of that capital by −10.3 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is −11.8% net margin on 0.37× asset turns.
FY26 ROCE is 3%, recovered from a FY14 trough of 3% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY26): −11.8% net margin × 0.37× asset turns × 1.84× balance-sheet leverage ≈ −8.0% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 1.7% − 12.0% = a −10.3 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Tata Chemicals Ltd carries total debt of ₹8,001 Cr against shareholder equity of ₹22,175 Cr as of Mar 26, a debt-to-equity of 0.36. On the annual view that ratio went from 0.37 in FY22 to 0.36 in FY26. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of ₹8,001 Cr against shareholder equity of ₹22,175 Cr — a debt-to-equity of 0.36. On the annual view, debt-to-equity went from 0.37 (FY22) to 0.36 (FY26). Read the returns on this page with that leverage in mind.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Foreign institutions cut 1.7 points of Tata Chemicals Ltd over 8 quarters, the biggest move on the register. That takes foreign institutions to 12.1% of the company. Domestic institutions moved +1.2 points over the same window, to 21.1%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: −1.7 points over 8 quarters to 12.1%; Domestic institutions: +1.2 points over 8 quarters to 21.1%; Promoters: +0.0 points over 8 quarters to 38.0%.
🚨 Why the register moved: foreign institutions drove it (−1.7 points), absorbed on the other side by domestic institutions (+1.2 points) — distribution into the market’s bid.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Tata Chemicals Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1TGV Sraac LtdTGVSL | 61.3/100Thin evidence · provisional57% evidence | 25.4/35 Revenue 18.2% · PAT 61.5% · OPM change 5 pp 53% evidence | 14.2/25 ROCE 10.4% · OPM 17% 57% evidence | 12.3/20 P/E 7.2× · PEG — 50% evidence | 9.4/20 RS sector 2.4% · RS bench -18.6% · 1Y -17.6%0 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 25.4 + 14.2 + 12.3 + 9.4 = 61.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 2Tuticorin Alkali Chemicals & Fertilizers LtdTUTICORALK | 56.0/100Mixed-positive evidence78% evidence | BREAKING OUT | 11.1/35 Revenue 9.1% · PAT -41.1% · OPM change -4.1 pp 83% evidence | 20.0/25 ROCE 22% · OPM 15.6% 76% evidence | 7.9/20 P/E 20.1× · PEG — 50% evidence | 17.0/20 RS sector 6% · RS bench 0.5% · 1Y -24.8%4 of 12 weeks ahead 100% evidence |
| Exact sum: 11.1 + 20 + 7.9 + 17 = 56 · Decision use: Price leads the evidence: RS versus the benchmark is 0.5%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 3Gujarat Alkalies & Chemicals LtdGUJALKALI | 55.4/100Mixed-positive evidence84% evidence | ASLEEP | 21.6/35 Revenue 7.1% · PAT 100% · OPM change 9 pp 74% evidence | 6.3/25 ROCE 1.4% · OPM 18% 100% evidence | 13.5/20 P/E 74.2× · PEG 0.15 65% evidence | 14.0/20 RS sector 19.6% · RS bench 14.7% · 1Y 12.9%6 of 12 weeks ahead 100% evidence |
| Exact sum: 21.6 + 6.3 + 13.5 + 14 = 55.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4GHCL LtdGHCL | 46.1/100Mixed-negative evidence90% evidence | ASLEEP | 8.6/35 Revenue -3.7% · PAT -24.2% · OPM change -6 pp 88% evidence | 18.1/25 ROCE 17.4% · OPM 22% 100% evidence | 11.7/20 P/E 8.8× · PEG 1.31 100% evidence | 7.7/20 RS sector -1% · RS bench -17.1% · 1Y -27.6%0 of 10 weeks ahead 70% evidence |
| Exact sum: 8.6 + 18.1 + 11.7 + 7.7 = 46.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Primo Chemicals LtdPRIMO | 46.1/100Mixed-negative evidence60% evidence | TURNING | 14.0/35 Revenue 1.1% · PAT 100% · OPM change -2.3 pp 62% evidence | 10.6/25 ROCE 6.5% · OPM 13.1% 95% evidence | 9.5/20 P/E 39.5× · PEG — 50% evidence | 12.0/20 RS sector — · RS bench 6.9% · 1Y —1 of 3 weeks ahead 25% evidence |
| Exact sum: 14 + 10.6 + 9.5 + 12 = 46.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Chemfab Alkalis LtdCHEMFAB | 37.0/100Mixed-negative evidence71% evidence | ASLEEP | 19.1/35 Revenue -16.2% · PAT 95.3% · OPM change 1.5 pp 95% evidence | 4.9/25 ROCE 1.6% · OPM 13.8% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.0/20 RS sector -29.6% · RS bench -20.8% · 1Y -51.5%3 of 10 weeks ahead 70% evidence |
| Exact sum: 19.1 + 4.9 + 10 + 3 = 37 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Tata Chemicals Ltdthis pageTATACHEM | 27.5/100Adverse evidence80% evidence | ASLEEP | 8.1/35 Revenue 2% · PAT -80% · OPM change -4 pp 100% evidence | 6.6/25 ROCE 3.4% · OPM 13% 100% evidence | 10.0/20 P/E — · PEG — 0% evidence | 2.8/20 RS sector -10.6% · RS bench -15% · 1Y -28.5%6 of 12 weeks ahead 100% evidence |
| Exact sum: 8.1 + 6.6 + 10 + 2.8 = 27.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Tata Chemicals Ltd's share price today?
Tata Chemicals Ltd trades at ₹674, −29.6% over the past year. The company is valued at ₹17,159 Cr. The stock sits at 18% of its 52-week range of ₹605–₹994, −10.9% versus its 200-day average. On the tape, the price is in a downtrend, 39 weeks in. — as of 31 July 2026.
What were Tata Chemicals Ltd's latest quarterly results?
Tata Chemicals Ltd reported revenue of ₹4,255 Cr and net profit of ₹60.0 Cr for the Jun 26 quarter. Revenue rose 14.4% and profit fell 81.0% year on year. The operating margin was 13.0%, 4.0 pp lower than a year earlier. — as of 31 July 2026.
What is Tata Chemicals Ltd's revenue?
Tata Chemicals Ltd reported revenue of ₹4,255 Cr in the Jun 26 quarter, +14.4% year on year. For the full FY26 fiscal year, revenue was ₹14,584 Cr (−2.0%). Over the last 10 years revenue compounded at −0.2% a year. — as of 31 July 2026.
What is Tata Chemicals Ltd's profit?
Tata Chemicals Ltd earned ₹60.0 Cr of net profit in the Jun 26 quarter, −81.0% year on year. Full-year FY26 profit was ₹−1,715 Cr. The operating margin ran 13.0% in the latest quarter. — as of 31 July 2026.
What is Tata Chemicals Ltd's market cap?
Tata Chemicals Ltd's market capitalisation is ₹17,159 Cr at a share price of ₹674. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is Tata Chemicals Ltd's P/E ratio?
Tata Chemicals Ltd trades at a P/E of 64.4×, at the 91st percentile of its own 10-year range, against a long-run median of 11.8×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does Tata Chemicals Ltd pay a dividend?
Not in its latest year — Tata Chemicals Ltd's dividend payout was 0% of profit in FY26. It did record a payout in 11 of its last 13 reported fiscal years, so there is a history but no current dividend. This page holds the payout ratio, not a per-share amount. — as of 31 July 2026.
Is Tata Chemicals Ltd overvalued?
On its own history, Tata Chemicals Ltd looks expensive against its own history: its P/E of 64.4× sits at the 91st percentile of its 10-year range (long-run median 11.8×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.
Is Tata Chemicals Ltd growing?
Not right now — Tata Chemicals Ltd's latest numbers are shrinking: latest-quarter revenue +14.4% year on year, profit −81.0%, and the margin −4.0 pp at 13.0%. The earnings engine currently reads: deteriorating — as of 31 July 2026.
How is Tata Chemicals Ltd performing?
Tata Chemicals Ltd is in a downtrend, 39 weeks in. Its latest quarter's revenue rose 14.4% and profit fell 81.0% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 7 weeks. This describes what the data did, not a rating. — as of 31 July 2026.
What stage is Tata Chemicals Ltd in?
Turning around — profit growth swung from −513.7% at the trough to −484.2% off a 1-quarter-old trough, ROCE holding at 3.1%. The read comes from the last 12 quarters of growth (revenue growth +2.0% latest, profit growth −484.2% latest, eps growth −742.7% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 31 July 2026.
Is Tata Chemicals Ltd in an uptrend?
No — the price is in a downtrend (week 39 of stage 4), trading −10.9% versus its 200-day average and at 18% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is Tata Chemicals Ltd beating the market?
Not lately — on a trailing-13-week view Tata Chemicals Ltd is currently behind the NIFTY 500 (7 weeks and counting; last ahead the week of 2026-06-24), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.4 years the stock moved +314% against the NIFTY 500's +264% — ahead of the index over the full window. — as of 31 July 2026.
Will Tata Chemicals Ltd's share price go up?
This page publishes no price forecast for Tata Chemicals Ltd. What it measures instead: the share price is ₹674, the price is in a downtrend 39 weeks in. Its P/E of 64.4× sits at the 91st percentile of its own 10-year range. — as of 31 July 2026.
Who owns Tata Chemicals Ltd?
Promoters hold 38.0% of Tata Chemicals Ltd, foreign institutions 12.1%, domestic institutions 21.1% and the public 28.8% (latest quarter). The biggest move on the register over the last two years: Foreign institutions cut 1.7 points over 8 quarters. — as of 31 July 2026.
Does Tata Chemicals Ltd have too much debt?
It is moderate — Tata Chemicals Ltd's debt-to-equity is 0.38, and operating profit covers the interest bill 3×. FY26 borrowings were ₹8,001 Cr against equity of ₹21,206 Cr. Read the returns on this page with that leverage in mind — as of 31 July 2026.
What is Tata Chemicals Ltd's capex?
Tata Chemicals Ltd spent ₹5,442 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹1,328 Cr, with ₹1,038 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is Tata Chemicals Ltd's cash flow?
Tata Chemicals Ltd generated ₹1,269 Cr of operating cash flow in FY26 and ₹−59.0 Cr of free cash flow after ₹1,328 Cr of capital spending. Reported profit that year was ₹−1,715 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is Tata Chemicals Ltd's profit real cash?
Yes — over the last 3 fiscal years, 238% of Tata Chemicals Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹1,269 Cr against reported profit of ₹−1,715 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 31 July 2026.
Where is Tata Chemicals Ltd in its business cycle?
Tata Chemicals Ltd's FY26 operating margin was 12.0%, against a 13-year band of 4.0%–33.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 13.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the Tata Chemicals Ltd story?
The sharpest disagreement: the price moved −29.6% in a year while annual EPS moved −907.0% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is Tata Chemicals Ltd a stock worth studying right now?
This is not investment advice. The machine read: Tata Chemicals Ltd's price has outrun its earnings. −29.6% in a year against EPS −907.0% — the market is paying now for delivery later. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.